Resistance of Bcr-Abl-positive leukemic stem cells (LSCs) to imatinib treatment in patients with chronic myeloid leukemia (CML) can cause relapse of disease and might be the origin for emerging drug-resistant clones. In this study, we identified Smo as a drug target in Bcr-Abl-positive LSCs. We show that Hedgehog signaling is activated in LSCs through upregulation of Smo. While Smo(-/-) does not impact long-term reconstitution of regular hematopoiesis, the development of retransplantable Bcr-Abl-positive leukemias was abolished in the absence of Smo expression. Pharmacological Smo inhibition reduced LSCs in vivo and enhanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML.
Interaction of cancer cells with their microenvironment generated by stromal cells is essential for tumor cell survival and influences the localization of tumor growth. Here we demonstrate that hedgehog ligands secreted by bone-marrow, nodal and splenic stromal cells function as survival factors for malignant lymphoma and plasmacytoma cells derived from transgenic Emu-Myc mice or isolated from humans with these malignancies. Hedgehog pathway inhibition in lymphomas induced apoptosis through downregulation of Bcl2, but was independent of p53 or Bmi1 expression. Blockage of hedgehog signaling in vivo inhibited expansion of mouse lymphoma cells in a syngeneic mouse model and reduced tumor mass in mice with fully developed disease. Our data indicate that stromally induced hedgehog signaling may provide an important survival signal for B- and plasma-cell malignancies in vitro and in vivo. Disruption of this interaction by hedgehog pathway inhibition could provide a new strategy in lymphoma and multiple myeloma therapy.
Rapid quantitative methods for characterizing small molecules, peptides, proteins, or RNAs in a broad array of cellular assays would allow one to discover new biological activities associated with these molecules and also provide a more comprehensive profile of drug candidates early in the drug development process. Here we describe a robotic system, termed the automated compound profiler, capable of both propagating a large number of cell lines in parallel and assaying large collections of molecules simultaneously against a matrix of cellular assays in a highly reproducible manner. To illustrate its utility, we have characterized a set of 1,400 kinase inhibitors in a panel of 35 activated tyrosine-kinasedependent cellular assays in dose-response format in a single experiment. Analysis of the resulting multidimensional dataset revealed subclusters of both inhibitors and kinases with closely correlated activities. The approach also identified activities for the p38 inhibitor BIRB796 and the dual src͞abl inhibitor BMS-354825 and exposed the expected side activities for Glivec͞STI571, including cellular inhibition of c-kit and platelet-derived growth factor receptor. This methodology provides a powerful tool for unraveling the cellular biology and molecular pharmacology of both naturally occurring and synthetic chemical diversity.drug discovery ͉ high-throughput screening ͉ tyrosine kinase T he ability to simultaneously interrogate the activities of a library of molecules against a large panel of cellular assays would provide a rapid efficient means to begin to characterize and correlate the biological properties of both natural and synthetic chemical diversity. For example, libraries of noncoding RNAs, mutant growth factors, small molecule kinase inhibitors, or even existing drugs could be assayed for their potency and selectivity in pathway-based or receptor screens or toxicity and metabolic stability in diverse cell types to discover a new biological activity or optimize the pharmacological properties of a molecule (1-3). Although whole-cell systems represent an attractive milieu to characterize gene and small-molecule function, no robust and systematic method exists to correlate chemical structure and biological activity across a large number of molecules and cellular assays. To address this problem, we have developed an approach that affords rapid cost-effective broad-based cellular profiling in parallel against molecular libraries. An industrial-scale automated compound profiling (ACP) system has been designed, which consists of an automated tissue culture system for propagating cell lines, integrated with a system for automatically performing miniaturized cell-based assays in 384-or 1,536-well microplates. The ACP can rapidly test thousands of arrayed molecules, in replicates, in doseresponse format against hundreds of unique cellular assays in a single experiment.To demonstrate this capability, we focused on the problem of identifying selective small-molecule inhibitors of protein tyrosine kinases. Tyrosine ...
Chronic Myeloid Leukemia is characterized by the expansion of a leukemic stem cell clone carrying a Philadelphia translocation, which outgrows the non-malignant haematopoietic stem cells. Here we show that BCR-ABL directly enhances self renewal of haematopoietic stem and progenitor cells by activating the hedgehog signaling pathway through upregulation of SMO. Induction of hedgehog signaling in regular bone marrow by overexpression of SMO or loss of PTCH induces expansion of short term repopulating cells, but also enhances the expansion of long term repopulating haematopoietic stem cells. Pharmacological inhibition of SMO activity in BCR-ABL positive bone marrow cultures induced apoptosis in BCR-ABL positive differentiated cells and inhibited colony forming capacity of BCR-ABL positive self renewing cells in vitro. While loss of SMO in regular haematopoiesis only impacts the reconstitution of CD8 positive T-cells and short term repopulating cells (transplantation of SMO−/− fetal liver cells), the development of BCR-ABL positive leukemias was impaired and retransplantability abolished in the absence of SMO expression. Combined treatment of leukemic mice with AMN107 (Abl inhibitor) and Cyclopamine (SMO inhibitor) lead to a reduction of Bcr-Abl positive self-renewing cells in vivo and enhanced the time to relapse more than 3-fold compared to mice treated with AMN107 alone. Thus we conclude that BCR-ABL enhances the self renewal of leukemic stem cells through intrinsic activation of hedgehog signaling by upregulation of SMO. Therefore Hh pathway inhibition alone or in combination with Abl inhibitors could serve as an effective therapeutic strategy to reduce the malignant stem cell pool in BCR-ABL positive leukemias.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.